Patient Diversity and Beyond: Tapping the Potential of the Asia Pacific for Clinical Trials

The Asia Pacific, which is home to more than 40% of the world’s population, is one of the most culturally diverse regions for clinical trials. Over the last 10 years it has become an increasingly attractive destination for clinical trials contributing almost 50% of new clinical trial activity globally in 2022 and looks poised to overtake ROW trials in 2023. There has also been a meaningful shift in APAC trials towards a greater proportion of early phase trials. The region has also taken the lead in cell and gene clinical trials, accounting for the largest share (>50%) of new trials in 2022. Access to vast and diverse patient pools is a key factor in this growth trend. In addition, the region has developed its trial infrastructure and capabilities, including clinical research networks.

Yet, the complexity of the clinical trial landscape in APAC demands specialist understanding to design and deliver appropriate trial strategies. This session brings together experts from industry and clinical trial institutions from the region to discuss the current state of play, and importantly, future developments and perspectives for successful clinical trial strategies in APAC.